The Efficacy of Sacubitril Valsartan Sodium Tablets in the Treatment of CHD Combined with CHF
Objective To investigate the efficacy of sacubitril valsartan sodium tablets in the treatment of coronary heart disease(CHD)complicated with chronic heart failure(CHF).Methods One hundred and fourteen patients with CHD combined with CHF who were treated in our hospital during the period from January 2022 to December 2023 were selected and divided into the control group(conventional treatment,57 cases)and the study group(conventional+sacubitril valsartan sodium tablets treatment,57 cases)by using the district group randomisati-on method.The efficacy,cardiac function,inflammatory factor levels,quality of life and adverse reactions were compared between the two groups.Result The total clinical effective rate of the study group was significantly higher than that of the control group(χ2=5.911,P<0.05).After 12 weeks of treatment,the left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)in the study group decreased,and the left ventricular ejection frac-tion(LVEF)increased.The LVESD and LVEDD in the study group were lower than those in the control group(P<0.05),and the LVEF was higher than that in the control group(P<0.05).After 12 weeks of treatment,the inflammatory factors tumor necrosis factor-α(TNF-α),high-sensi-tivity C-reactive protein(hs CRP),interleukin-1β(IL-1β),and interleukin-6(IL-6)in both groups significantly decreased,and the levels of TNF-α,hs CRP,IL-1β,and IL-6 in the study group were lower than those in the control group(P<0.05).After 12 weeks of treatment,the 6-minute walking distance(6MWT)of both groups significantly increased(P<0.05),and the Minnesota Heart Failure Quality of Life Questionnaire(MLHFQ)score significantly decreased(P<0.05).The 6MWT of the study group was higher than that of the control group,and the ML-HFQ was lower than that of the control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacu-bitril valsartan sodium tablets for patients with CHD combined with CHF can effectively en-hance cardiac function and further improve the overall health and quality of life of patients by lowering the levels of inflammatory factors such as TNF-α,IL-1β and IL-6.
万方数据
